Skip to main content

Progressive Keratoconus

1
Pipeline Programs
2
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

TBF Genie Tissulaire
TBF Genie TissulaireFrance - Mions
1 program
1
Therapeutic lens alonePhase 31 trial
Active Trials
NCT06450470Recruiting116Est. Nov 2025
Glaukos
GlaukosALISO VIEJO, CA
3 programs
NXL Energy 1PHASE_1_21 trial
Test Article APHASE_31 trial
riboflavin ophthalmic solutionPHASE_31 trial
Active Trials
NCT05314738Recruiting150Est. Feb 2026
NCT03442751Completed201Est. Aug 2020
NCT00647699Completed147Est. Apr 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TBF Genie TissulaireTherapeutic lens alone
GlaukosTest Article A
Glaukosriboflavin ophthalmic solution
GlaukosNXL Energy 1

Clinical Trials (4)

Total enrollment: 614 patients across 4 trials

NCT06450470TBF Genie TissulaireTherapeutic lens alone

Use of a Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive Keratoconus

Start: Nov 2024Est. completion: Nov 2025116 patients
Phase 3Recruiting
NCT03442751GlaukosTest Article A

Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

Start: Apr 2018Est. completion: Aug 2020201 patients
Phase 3Completed
NCT00647699Glaukosriboflavin ophthalmic solution

Corneal Collagen Cross-linking for Progressive Keratoconus

Start: Dec 2007Est. completion: Apr 2011147 patients
Phase 3Completed
NCT05314738GlaukosNXL Energy 1

Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus

Start: Mar 2022Est. completion: Feb 2026150 patients
Phase 1/2Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 614 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.